SEATTLE, Nov. 12, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has added Ryan Montecucco as General Counsel and Secretary. “We are very pleased to have Ryan join our team,” stated Clark Tedford, Ph.D., President and CEO. “Ryan has been… Continue reading
SEATTLE, Sept. 10, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is collaborating with Diopsys, a leading provider of modern visual electrophysiology solutions. Diopsys’ technology helps eye care professionals accurately and objectively measure retinal and visual pathway function. The… Continue reading
SEATTLE, Sept. 3, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute… Continue reading
SEATTLE, July 8, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage private medical device company, creating a multi-wavelength photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed its Series C financing. The company raised approximately $14M to support further commercialization of its Valeda Light Delivery System for the treatment for dry… Continue reading
SEATTLE, Feb. 18, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in Diabetic Retinopathy (DR). “Recent research in our labs in both preclinical… Continue reading
SEATTLE, Jan. 23, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has added Daniel Bertholet to the Board of Directors. “We are very excited to have Daniel Bertholet join our Board of Directors,” stated Clark Tedford, Ph.D., President and CEO.… Continue reading
SEATTLE, Jan. 13, 2020 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has closed the 2nd tranche of its Series C round of financing. The proceeds of the financing are being used to support further clinical testing and commercialization of its… Continue reading
SEATTLE, Oct. 1, 2019 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has begun enrolling patients in a multi-center United States clinical study in dry Age-Related Macular Degeneration (AMD) patients. The randomized, multi-center study called LIGHTSITE III enrolled and treated the… Continue reading
SEATTLE, June 12, 2019 /PRNewswire/ — LumiThera, Inc. and Product Creation Studio today announced that LumiThera’s Valeda Light Delivery System has been honored with a silver award in the 21st Annual Medical Design Excellence Awards competition. The 2019 winners were announced at the MDEA Ceremony on Tuesday, June 11, 2019 in conjunction with the MD&M… Continue reading
SEATTLE, April 11, 2019 /PRNewswire/ — LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has begun enrolling patients in a European Union multi-center clinical study in dry Age-Related Macular Degeneration (AMD) patients. The randomized, multi-center, post-marketing study called LIGHTSITE II enrolled and treated… Continue reading
